Synairgen slumps as inhaled COVID drug fails pivotal test

UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people hospitalised with COVID-19.

Synairgen starts dosing inhaled COVID-19 drug in phase 3 tri...

UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19

Synairgen's inhaled drug cuts chances of COVID-19 progressin...

An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease. 

Synairgen doses first patients with COVID-19 drug

Duo of UK firms announce coronavirus therapy trials

Two UK firms have announced plans to begin trials of therapies to tackle the coronavirus outbreak.

Synairgen under the weather after AZ halts asthma trial

Shares in UK biotech Synairgen have dived after AstraZeneca halted a phase 2a trial for its asthma drug, AZD9412, because it had failed to generate efficacy data.